Healthcare

The past few years have witnessed huge strides in healthcare innovation, especially with the rapid rise of medtech and biotech. This innovation comes into play at all levels: from diagnosis to therapy and how the health system itself is actually organised. Connected objects, robotics, nanotechnologies, artificial intelligence — the potential for innovation is enormous and the Carnot Institutes are investing in the research needed to build the healthcare systems of both the present and the future.

GetBack

Protective sports and mobility clothing
Partnership Carnot STAR Institute - GetBack Sports Entreprise

No passive protective clothing has been developed specifically for cyclists and skiers and existing solutions tend to be highly restrictive and unpopular. In light of new mobility challenges and the increasing societal importance of sport, GetBack Sports has teamed up with the Carnot STAR Applied Biomechanics Institute to reinforce the scientific dimension of its product development.

Harnessing “Organs-On-Chips” technologyfor biomedical research Organs-

La technologie des «organes-sur-puce» au service de la recherche biomédicale
Partnership Carnot Pasteur MS Institute - Entreprise Emulate

Organs-On-Chips technology is viewed as revolutionary for biomedical research and involves recreating the function of tissues and organs in vitro within a miniaturised system. It provides a good model for studying basic mechanisms and pathophysiological processes while reducing the need for animal experiments. There are numerous potential industrial applications: search for drug candidates, development of therapeutic products, regenerative medicine, research into metabolic pathways and nutrition, etc.

IPC-3D

An R&D platform at the leading edge of leukaemia treatment
Partnership Carnot OPALE Institute - Imcheck Therapeutics Entreprise

Within Carnot OPALE institute, the IPC-Drug Discovery and Development programme (IPC-3D) offers a unique platform catering to the needs of players in the biopharmaceutical sector. IPC-3D is focused exclusively on the key issues involved in their pipeline development, from identification of new therapeutic targets through early evaluation of drug candidates in humans.

Presentation
Video
Fermer

IPC-3D

ALTUS

Diagnosing lung diseases using ultrasound imaging and AI
Carnot LSI Institute — Carnot preparing the future

ALTUS has been developed by Carnot LSI researchers amidst the health crisis to perform novel pulmonary diagnoses that combine ultrasound image analysis and AI. It harnesses an array of ultrasonic sensors covering the area of interest for tomography and automatic signal processing. It offers a customised and rapid framework for the detection of lung diseases, including Covid-19.

FLUDARABINE

New PET lymphoma imaging application
Carnot I2C Institute - Carnot preparing the future

[18F] Fludarabine has strong potential in PET imaging for detecting haematological malignancies, including lymphomas. This radiopharmaceutical can be used to visualise lymphoid tumour cells in situations where other diagnostic techniques remain limited in terms of specificity and sensitivity.

Cinesteam®

Absorbent anti-odour dressing
Partnership Carnot Curie Cancer Institute - Cemag Care Entreprise

Cinesteam® absorbent anti-odour dressing provides effective treatment of malodorous wounds by absorbing bad odours and exudates and emitting a pleasant cinnamon smell to enhance the everyday environment of both patients and carers. It has been developed by Cemag Care based on research carried out by Isabelle Fromantin, nurse and researcher at Carnot Curie Cancer Institute.

AsiDNA™

A new category of drugs to tackle DNA damage
Partnership Carnot Curie Cancer Institute - ONXEO Entreprise

AsiDNA™ harnesses strong innovation potential for patients suffering from different types of cancer. So how does it work? AsiDNA™ disrupts and depletes the ability of tumour cells to repair their DNA by diverting them from their target as soon as damage is detected.

Presentation
Video
Fermer

AsiDNA™Une nouvelle classe de médicaments pour répondreaux dommages de l’ADN

SCIPIO BIOSCIENCES KIT

A single-cell resolution RNA sequencing kit for all workbenches
Carnot Brain Institute — Carnot preparing the future

RNA sequencing at individual cell level makes it possible to characterise a cell, clarify its functions and track the progress of an illness. This sequencing is currently based on complex, costly instruments not readily available to researchers. Scipio bioscience has developed a revolutionary kit that provides similar data but is accessible to any scientist.

MACRILEN TM

Molecule for growth hormone dosage
Carnot Enterprise partnership Carnot Chimie Balard Cirimat Institute - AETERNA ZENTARIS

Growth hormone (GH) deficiency is attributable to a problem with the hypothalamic-pituitary axis, which may be characterised by damage to the hypothalamus or pituitary gland. Before now, there was no straightforward way to regulate the dose of the hormone produced by the pituitary gland, however, Aeterna Zentaris has come up with MacrilenTM, an orally ingestible solution.

ABILYCARE

A solution for detecting risks of fragility
Partnership Carnot Cognition Institute - Engie Ineo Enterprise

This solution was developed by Carnot Cognition’s Centre Borelli (merger of Cognac-G and CMLA labs) in partnership with Engie Ineo, and it can be used to assess the robustness of individuals using questionnaires and tests of an individual’s balance, walking skills and strength. It assesses fragility as part of diagnostic support: algorithms “factualise” clinical data and help health professional assess an individual’s fragility.

COVIDISC

A quick and reliable Covid test
Carnot IPGG Microfluidique Institute — Carnot preparing the future

Imagine a portable Covid test costing just ten dollars that gives results in less than an hour, and with a sensitivity equivalent to that of a PCR test. But this technology, which is set to shake up the diagnostics industry, is no pipedream and it already exists here in France. Its effectiveness has recently been proven and it is now undergoing numerous checks with a view to launching production in the near future.

NEURONAUTE®

Carnot Enterprise partnership Carnot Brain Institute - BioSerenity

BioSerenity’s mission is to provide doctors and patients with round-the-clock care. The care in question is based on the acquisition and analysis of electrophysiology tests such as EEGs (electroencephalograms), ECGs (electrocardiograms) and PSGs (polysomnography) performed using connected clothing that patients may wear at home over a long period of time. Data is uploaded to a secure hosting platform that doctors may access at any time.

SONOCLOUD®

Ultrasounds that make vessels more permeable
Carnot Enterprise partnership Carnot Brain Institute- Carthera

SonoCloud® is a medical implant designed by Professor Alexandre Carpentier, a neurosurgeon at La Pitié-Salpêtrière Hospital in Paris. It is inserted into the lining of the skull and activated iteratively during chemotherapy sessions using a transdermal microneedle and then connected to an external programmable generator. Ultrasounds are emitted inside the brain — without any bony obstacles — to allow the blood–brain barrier to be opened temporarily.

LDH

Lymphoma Data Hub
Carnot CALYM Institute — Carnot preparing the future

As well as often being fragmented, big health data is of varying quality, incompatible in format and governed by disparate rules. This makes it harder to use and stifles the potential of AI, leading to lost opportunities in terms of competitiveness and research partnerships. The Lymphoma Data Hub aims to provide solutions to the problems encountered in lymphoma R&D projects.

HEPCAR

Identification of biomarkers in hepatocarcinoma cell lines using AI
Carnot Enterprise partnership Carnot AP-HP Institute -Owkin

The aim of this project was to study the clinical features of liver cancer sufferers. The findings of this research partnership between AP-HP and Owkin were published in the Hepatology scientific journal: “Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides” 

LENSFREE

"Lensless" imagining
Carnot CEA LETI Institute — Carnot preparing the future

Thanks to its extra large field of vision and compactness, Carnot CEA LETI’s lensless imager enables healthcare professionals to perform analyses at the patient’s bedside rather than in a lab. The technology is also at least ten times cheaper than an optical microscope and is capable of analysing 10 000 biological objects at the same time. This innovation is protected by 25 different patents.